Maternal folic acid supplementation and the risk of ankyloglossia (tongue-tie) in infants; a systematic review
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0294042 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, 2023. Verfasst von Gal Rubin und 6 weiteren Autor:innen. Beteiligte Einrichtung: UCL EGA Institute for Women's Health, Reproductive Health Research Dept, UCL, London, United Kingdom. Hauptthemen laut MEDLINE: Ankyloglossia, Neural Tube Defects. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Maternal folic acid supplementation is protective against the development of neural tube defects (NTDs) in babies. However, recent public-facing communications have raised concerns about a causal relationship between folic acid supplementation, particularly after the first trimester, and ankyloglossia (tongue-tie) in infants. Non-evidence-based communications are potentially harmful because they could adversely affect adherence to folic acid supplementation, increasing NTD occurrence. This study aimed to review evidence on the relationships between maternal folic acid supplementation during preconception and/or pregnancy and the risk of ankyloglossia in infants.
Methods
We searched the databases MEDLINE, EMBASE, Cochrane CENTRAL, and Scopus. We searched for observational, and interventional studies, and systematic reviews investigating the effect of maternal folic acid supplementation during preconception or pregnancy on the occurrence of ankyloglossia in offspring. The search was registered on PROSPERO on 01/12/2022, ID: CRD42022375862.
Results
The database searches yielded 93 articles. After removing duplicates and screening titles and abstracts, 26 remained. One article was judged relevant for inclusion in analyses; a case-control study that directly mentions the relationship between folic acid supplementation and ankyloglossia . This study r eported that regular intake of folic acid supplements was higher in women with infants with ankyloglossia. However, this study has limitations regarding design, selection bias, and confounding, calling the findings into question.
Conclusions
Insufficient evidence exists for a relationship between folic acid supplementation and ankyloglossia. Currently, the benefits of folic acid supplementation far outweigh the risks. This must be clearly communicated to patients by their clinicians during preconception and antenatal care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UCL EGA Institute for Women's Health, Reproductive Health Research Dept, UCL, London, United Kingdom.
- Minerva University: College of Natural Sciences, San Francisco, CA, United States America.
- Centre for Public Health, Institute for Global Food Security, Queen's University Belfast, Belfast, Ireland.
- MRC Lifecourse Epidemiology Centre and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
ORCID-Profile: Gal Rubin, Catherine Stewart, Geraldine Barrett, Jennifer Hall
Zitieren
APA
Rubin, G., Stewart, C., McGowan, L., Woodside, J. V., Barrett, G., Godfrey, K. M., & Hall, J. (2023). Maternal folic acid supplementation and the risk of ankyloglossia (tongue-tie) in infants; a systematic review. PLOS ONE. https://doi.org/10.1371/journal.pone.0294042
Vancouver
Rubin G, Stewart C, McGowan L, Woodside JV, Barrett G, Godfrey KM, et al. Maternal folic acid supplementation and the risk of ankyloglossia (tongue-tie) in infants; a systematic review. PLOS ONE. 2023. doi:10.1371/journal.pone.0294042
BibTeX
@article{Rubin2023,
author = {Rubin, Gal and Stewart, Catherine and McGowan, Laura and Woodside, Jayne V and Barrett, Geraldine and Godfrey, Keith M and Hall, Jennifer},
title = {Maternal folic acid supplementation and the risk of ankyloglossia (tongue-tie) in infants; a systematic review},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0294042}
}
EUVIMED